Compare Incyte Corporation (INCY) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs The Coca-Cola Co K — how do they compare? Incyte Corporation trades at $117.95 (market cap $23.11B), while The Coca-Cola Co K trades at $82.1 (market cap $353.32B). The key difference: The Coca-Cola Co K is far larger — about 15.3× Incyte Corporation's market cap, and The Coca-Cola Co K pays a 2.58% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | KO | |
|---|---|---|
Market Cap | $23.11B | $353.32B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $84.92 |
52-Week Low | $67.38 | $65.67 |
Enterprise Value | $19.13B | $383.39B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Coca-Cola (KO) trades at $82.08, up 0.64% on the day, with a bullish analyst consensus and strong earnings beats in recent quarters. The stock shows robust profitability with a 27.8% net margin and 45.8% ROE, though valuations like a P/E of 25.82 are elevated. Technicals are mixed with a bearish overall signal but support near $82. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
Outlook remains positive given consistent dividend growth, earnings outperformance, and a $90.67 price target. Risks include high debt levels and regional demand volatility. The stock offers stability for income investors but faces valuation pressures amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
